Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua S Davis

Showing results (11-20 of 210) with videos related to

Pageof 21
Sort By:
Breathe (Sheffield, England)|January 15, 2021
Pro: Bronchoscopy is essential for pulmonary infections in patients with haematological malignanciesEliza J T Milliken, Joshua S Davis
The Medical Journal of Australia|February 14, 2024
Prosthetic joint infection diagnosis in an age of changing clinical patterns of infection and new technologiesJoshua S Davis, David Dewar, Laurens Manning
Open Forum Infectious Diseases|March 7, 2018
Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV CoinfectionNilar Lwin, Michael Boyle, Joshua S Davis
Infection, Disease & Health|September 11, 2019
CRyptOcoccosis in Newcastle and the hUnTer (CRONUT) - An epidemiological studyCarly M Hughes, Daniel Lennon, Joshua S Davis
The Medical Journal of Australia|July 9, 2013
Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern TerritoryJoshua S Davis, Anuja C Kulatunga, Krispin Hajkowicz
Infection, Disease & Health|April 17, 2023
Have gloves and gowns had their day? An Australian and New Zealand practice and attitudes survey about contact precautions for MRSA and VRE colonisationSarah Browning, Joshua S Davis, Brett G Mitchell
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2022
Correct Calculation of Confidence Interval for Proportion of Superior Comparisons Between Desirability of Outcome Ranking ScoresMark R Loewenthal, Joshua S Davis, Michael Dymock
Current Opinion in Critical Care|August 29, 2023
Optimal drug therapy for Staphylococcus aureus bacteraemia in adultsAmy Legg, Joshua S Davis, Jason A Roberts
The Medical Journal of Australia|April 14, 2017
Death from an untreatable infection may signal the start of the post-antibiotic eraCheryl A Jones, Joshua S Davis, David Fm Looke
Hepatology (Baltimore, Md.)|November 8, 2014
Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?Carla Silva, Elizabeth Ianna, Tracey Jones, et al.
Pageof 21

Showing results (11-20 of 210) with videos related to

Sort By:
Pageof 21
Breathe (Sheffield, England)|January 15, 2021
Pro: Bronchoscopy is essential for pulmonary infections in patients with haematological malignanciesEliza J T Milliken, Joshua S Davis
The Medical Journal of Australia|February 14, 2024
Prosthetic joint infection diagnosis in an age of changing clinical patterns of infection and new technologiesJoshua S Davis, David Dewar, Laurens Manning
Open Forum Infectious Diseases|March 7, 2018
Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV CoinfectionNilar Lwin, Michael Boyle, Joshua S Davis
Infection, Disease & Health|September 11, 2019
CRyptOcoccosis in Newcastle and the hUnTer (CRONUT) - An epidemiological studyCarly M Hughes, Daniel Lennon, Joshua S Davis
The Medical Journal of Australia|July 9, 2013
Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern TerritoryJoshua S Davis, Anuja C Kulatunga, Krispin Hajkowicz
Infection, Disease & Health|April 17, 2023
Have gloves and gowns had their day? An Australian and New Zealand practice and attitudes survey about contact precautions for MRSA and VRE colonisationSarah Browning, Joshua S Davis, Brett G Mitchell
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2022
Correct Calculation of Confidence Interval for Proportion of Superior Comparisons Between Desirability of Outcome Ranking ScoresMark R Loewenthal, Joshua S Davis, Michael Dymock
Current Opinion in Critical Care|August 29, 2023
Optimal drug therapy for Staphylococcus aureus bacteraemia in adultsAmy Legg, Joshua S Davis, Jason A Roberts
The Medical Journal of Australia|April 14, 2017
Death from an untreatable infection may signal the start of the post-antibiotic eraCheryl A Jones, Joshua S Davis, David Fm Looke
Hepatology (Baltimore, Md.)|November 8, 2014
Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?Carla Silva, Elizabeth Ianna, Tracey Jones, et al.
Pageof 21